| Item Type | Name |
|
Concept
|
Fusion Proteins, bcr-abl
|
|
Academic Article
|
Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: chronic myelogenous leukemia presenting in lymphoid blast vs Ph+ acute lymphoblastic leukemia.
|
|
Academic Article
|
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
|
|
Academic Article
|
Pseudo-Gaucher histiocytes identified up to 1 year after transplantation for CML are BCR/ABL-positive.
|
|
Academic Article
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
|
|
Academic Article
|
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
|
|
Academic Article
|
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
|
|
Academic Article
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
|
|
Academic Article
|
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
|
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
|
Academic Article
|
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
|
|
Academic Article
|
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
|
|
Academic Article
|
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
|
|
Academic Article
|
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
|
|
Academic Article
|
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
|
|
Academic Article
|
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
|
|
Academic Article
|
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
|
|
Academic Article
|
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
|
|
Academic Article
|
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
|
|
Academic Article
|
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
|
|
Academic Article
|
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
|
|
Academic Article
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
|
Academic Article
|
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
|
|
Academic Article
|
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
|
|
Academic Article
|
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.
|
|
Academic Article
|
Is there a best TKI for chronic phase CML?
|
|
Academic Article
|
Is there a best TKI for chronic phase CML?
|
|
Academic Article
|
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
|
|
Academic Article
|
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
|
|
Academic Article
|
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
|
|
Academic Article
|
Imatinib is still recommended for frontline therapy for CML.
|
|
Academic Article
|
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
|
|
Academic Article
|
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
|
|
Academic Article
|
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
|
|
Academic Article
|
Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis.
|